Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Willis C, Bauer H, Au TH, Menon J, Unni S, Tran D, Rivers Z, Akerley W, Schabath MB, Badin F, Sekhon A, Patel M, Xia B, Gustafson B, Villano JL, Thomas JM, Lubinga SJ, Cantrell MA, Brixner D, Stenehjem D. Willis C, et al. Among authors: lubinga sj. Oncotarget. 2022 Dec 6;13:1306. doi: 10.18632/oncotarget.28318. Oncotarget. 2022. PMID: 36473137 Free PMC article. No abstract available.
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M, Chaudhary MA, Yuan Y, Varol N, Dale P, Testa E, Klint J, Lee A, Lubinga SJ, Penrod JR. Berling M, et al. Among authors: lubinga sj. J Med Econ. 2022 Jan-Dec;25(1):703-711. doi: 10.1080/13696998.2022.2077549. J Med Econ. 2022. PMID: 35659172 Free article.
Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M, Sandhu H, Maervoet J, Yuan Y, Chaudhary MA, Varol N, Lee A, Dale P, Jones C, Lubinga SJ, Penrod JR. Polyzoi M, et al. Among authors: lubinga sj. J Med Econ. 2022 Jan-Dec;25(1):660-668. doi: 10.1080/13696998.2022.2048573. J Med Econ. 2022. Update in: J Med Econ. 2022 Jan-Dec;25(1):703-711. doi: 10.1080/13696998.2022.2077549 PMID: 35658806 Free article. Updated.
Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Willis C, Bauer H, Au TH, Menon J, Unni S, Tran D, Rivers Z, Akerley W, Schabath MB, Badin F, Sekhon A, Patel M, Xia B, Gustafson B, Villano JL, Thomas JM, Lubinga SJ, Cantrell MA, Brixner D, Stenehjem D. Willis C, et al. Among authors: lubinga sj. Oncotarget. 2022 Jan 31;13:257-270. doi: 10.18632/oncotarget.28178. eCollection 2022. Oncotarget. 2022. PMID: 35111281 Free PMC article.
31 results